Walk down any supplement aisle and the omega-3 section reads like a competition in milligrams. Patients reasonably assume that the bigger number on the front of the bottle means more EPA and DHA in their bloodstream. The reality is more nuanced. The chemical form in which the fatty acids are delivered shapes how well the body absorbs them, how stable they are on the shelf, and how much of what was paid for actually reaches the tissues that need it. Two products with identical 1,000 mg labels can deliver wildly different plasma omega-3 levels at the same dose. This is the practitioner’s primer on what is actually in the bottle — and how to read the label that tells you.
Why omega-3s matter clinically
EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are long-chain omega-3 fatty acids the body cannot manufacture in meaningful amounts. They are structural components of cell membranes — particularly concentrated in the brain, retina, and cardiovascular tissue — and they are precursors to specialised pro-resolving mediators (SPMs) that actively resolve inflammation rather than just suppress it. Adequate omega-3 status correlates with cardiovascular resilience, healthier triglyceride profiles, cognitive support, joint comfort, and modulation of inflammatory conditions across the literature.
Most modern diets, particularly urban Indian diets, are heavily skewed toward omega-6 fats from refined seed oils — sunflower, soya, corn, safflower. The resulting omega-6 to omega-3 ratio is consistently inflammatory across population samples. Closing that gap is the clinical rationale behind supplementation when dietary intake of fatty fish (or algae-based equivalents) falls short.
EPA and DHA — different roles, different doses
It is worth noting that EPA and DHA are not interchangeable. EPA is the more anti-inflammatory of the two and dominates the protocols for mood, cardiovascular, and inflammatory conditions. DHA is the structural lipid of the brain and retina and matters most for cognitive support, eye health, and pregnancy/early development. A product that is heavy on one and light on the other may be wrong for the patient even if the total omega-3 number looks right. Read the ratio, not just the sum.
The three chemical forms decoded
Almost every omega-3 product on the market falls into one of three chemical classes — and the form determines bioavailability.
Natural triglycerides (TG)
This is the form omega-3s exist in inside a living fish. Each glycerol backbone holds three fatty acids, including EPA and DHA. Fish oils sold in their natural triglyceride form are minimally processed — typically only filtered and deodorised. Concentration of EPA + DHA is moderate (30–40% of total fatty acids). The remaining ~60% is other fish-derived fats that are not biologically inert but add caloric load without therapeutic value.
Ethyl esters (EE)
To create high-concentration products, manufacturers strip the fatty acids off the glycerol backbone and attach them to ethanol, producing ethyl ester molecules. This chemistry allows EPA and DHA to be selectively concentrated to 60–85% of total fatty acids. Most of the high-dose, low-cost fish oils on the market are ethyl esters, even when the label does not state it plainly — the cost difference per gram of EPA + DHA produced is significant.
Re-esterified triglycerides (rTG) and monoglycerides (MAG)
After concentration, some manufacturers reattach the fatty acids to a glycerol backbone, restoring a triglyceride structure (rTG). Monoglyceride forms (MAG) attach a single fatty acid to glycerol — a structure the body produces naturally during fat digestion, meaning the absorption step is partially “pre-done.” Both rTG and MAG are more expensive to manufacture than EE, but both restore the bioavailability advantage of the natural structure while keeping the concentration benefit of the EE process.
The bioavailability gap — what the research actually shows
Head-to-head studies consistently show that natural triglyceride and re-esterified triglyceride forms produce higher plasma EPA and DHA than ethyl esters at equivalent doses. The mechanism is straightforward: digestion requires pancreatic lipase to hydrolyse the fatty acids before they can be absorbed, and that enzymatic process operates more efficiently on triglyceride and monoglyceride structures than on ethyl esters. EE forms require additional enzymatic steps that some patients — particularly older adults, those with low pancreatic output, or those on chronic acid suppression — perform suboptimally.
The difference is not academic. Published comparisons report absorption advantages on the order of 24–70% favouring triglyceride forms, with monoglyceride forms reporting even higher bioavailability in some studies. For a patient on a therapeutic dose (typically 2–4 g/day of combined EPA + DHA for clinical effect on inflammation, mood, or cardiovascular markers), this gap is the difference between a supplement that moves blood markers and one that produces expensive urine.
Ethyl esters are not useless. They can still raise the omega-3 index when dosed appropriately and taken with a fat-containing meal — which dramatically improves their absorption. They are simply less efficient per milligram, which matters when the dose has to be therapeutic rather than aspirational.
The omega-3 index — measure, do not guess
One of the most underused tests in clinical practice is the omega-3 index — a measure of EPA + DHA as a percentage of total red blood cell fatty acids. Unlike serum omega-3 levels, which fluctuate hourly with intake, the omega-3 index reflects tissue saturation over the preceding 3–4 months — comparable to HbA1c for glucose.
Target: omega-3 index >8%. Below 4% is considered high cardiovascular risk; 4–8% is intermediate. Most Indian patients, especially vegetarians and those on lower fatty-fish intake, sit in the 3–5% range at baseline. The test is now widely available (Quest, OmegaQuant, several Indian labs) at around ₹2,500–4,000. For any patient on therapeutic omega-3 supplementation, a baseline + 12-week recheck demonstrates whether the chosen product is actually working. It is the kind of measurement that distinguishes a clinical protocol from a wellness recommendation.
How to read a fish oil label (and the vegetarian alternative)
A useful label disclosure includes five things:
- The chemical form — TG, rTG, MAG, or EE, stated explicitly. Vague language (“highly concentrated fish oil”) usually means EE.
- EPA and DHA content per softgel — not just “fish oil 1,000 mg” (the classic misdirection — a 1,000 mg softgel may contain only 300 mg of actual EPA + DHA).
- Source species and harvesting region — small, short-lived fish (anchovies, sardines, mackerel) carry lower heavy-metal load than large predatory species. Krill oil and squid oil are credible alternatives with their own profiles.
- Third-party oxidation testing — peroxide value (PV), anisidine value (AV), and TOTOX (PV + AV). Reputable manufacturers publish these per batch.
- Manufacturing and expiry dates — omega-3s oxidise with age even sealed; an expiry date 4 years out on a fish oil bottle is a marketing claim, not a chemistry claim.
The vegetarian alternative — algae-based EPA and DHA
For vegetarian and vegan patients, ALA-rich plant sources (flax, chia, walnut) are not adequate substitutes for direct EPA + DHA — the conversion rate of ALA to EPA is roughly 5–10% in humans, and ALA to DHA is essentially negligible. Algae-based EPA + DHA is the credible vegetarian alternative. Manufactured from cultivated microalgae (the same organisms that produce omega-3s in fish in the first place), it delivers identical EPA and DHA structures in a fully plant-based form, with no heavy-metal contamination risk. Doses are equivalent to fish-derived products. The omega-3 index responds the same way. For Indian practitioners working with vegetarian patient populations, this should be the default option, not an afterthought.
Freshness — the underrated quality marker
Beyond chemical form, the freshness of an omega-3 supplement matters enormously. An oxidised omega-3 product is not just less effective — it actively contributes to oxidative stress, the exact mechanism the supplement was meant to modulate. The pattern of recommending generic high-dose fish oil to inflammation patients and seeing them get worse over months is often this dynamic playing out. Smell is a reasonable patient-level check (a fresh fish oil should smell of nothing or faintly of the sea; a fish oil that smells strongly fishy is rancid). The clinical check is the manufacturer’s certificate of analysis, with TOTOX value below 26 considered the accepted freshness threshold.
This is the same evaluation logic that applies across supplement categories — product specificity matters more than the headline number on the label. We cover the same dynamic in probiotics, where strain and CFU specificity matters more than total dose, in our piece on probiotic strain specificity.
Omega-3 supplementation is a place where practitioner expertise produces outsized patient value — because the patient cannot evaluate chemical form, oxidation status, or third-party verification on their own, and the marketing universally misleads. A clinician who recommends 2 g/day of EPA + DHA in rTG or MAG form, from anchovy/sardine source, with a TOTOX below 20, re-tested at 12 weeks via omega-3 index — is doing the kind of specific, evidence-anchored work that distinguishes a serious clinical practice from a wellness recommendation. At Horta Nutrition, we manufacture omega-3 formulations (both fish-derived and algae-based) under our nutraceutical contract programme with full form disclosure, oxidation testing, and stability data per batch — so practitioners can recommend products whose actual contents they can vouch for. If you want to discuss product evaluation for a specific patient case, the Horta practitioner network includes peer access for protocol consultation.
